Clinical trials: Urinary Bladder Diseases
Urinary Bladder, Overactive
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended…
- Trial name
- NCT01054222
- Testing
- Fesoterodine
- Where
- 3 sites in Portugal
- Volunteers
- 31 people
- Sponsor
- Pfizer
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Non Muscle Invasive Bladder Cancer
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
- Trial name
- NCT05981131
- Testing
- N803 plus Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Urinary Bladder, Overactive
UK Study Assessing Flexible Dose Fesoterodine in Adults
To explore the effects of fesoterodine when used in a flexible dose manner
- Trial name
- SAFINA (NCT00806494)
- Testing
- Fesoterodine
- Where
- 39 sites in United Kingdom
- Volunteers
- 331 people
- Sponsor
- Pfizer
Hematuria, Dysuria
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in the urine of patients suspected of having bladder cancer.
- Conditions
- Hematuria, Dysuria, Bladder Cancer
- Trial name
- NCT01563796
- Where
- United States
- Volunteers
- 1,115 people
- Sponsor
- Medical Diagnostic Laboratories, LLC
Overactive Bladder, Nocturia
NOGO for an Overactive Bladder
This is a double-blind, randomized and placebo-controlled study to evaluate the safety and effectiveness of NoGo, a standardized extract from Angelica archangelica, on overactive bladder
- Trial name
- NOGO-OAB (NCT04357223)
- Testing
- extract from Angelica archangelica leaf
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- SagaNatura
Cystitis, Interstitial
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary…
- Trial name
- NCT00999518
- Testing
- Tanezumab
- Where
- 171 sites in United States, Belgium and 12 more
- Volunteers
- 205 people
- Sponsor
- Pfizer
Overactive Bladder
SSR240600C Treatment in Women With Overactive Bladder
The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
- Trial name
- BILADY (NCT00564226)
- Testing
- SSR240600C, tolterodine
- Where
- 7 sites in United States, Canada and 5 more
- Volunteers
- 345 people
- Sponsor
- Sanofi
Overactive Bladder
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index…
- Trial name
- NCT01737684
- Testing
- Vibegron
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
- Trial name
- REMOTE (NCT01302938)
- Testing
- Tolterodine ER
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Solid Tumor, Adult, Bladder Cancer
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian…
- Conditions
- Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT06337084
- Testing
- MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Monopar Therapeutics
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Stress Urinary Incontinence (SUI)
A Study of Two Versions of the Uresta Pessary Handle for Women With Stress Urinary Incontinence
The goal of this clinical trial is to learn if a new handle design for the uresta pessary works better than the current handle design for women when they are using the pessary.
- Trial name
- NCT07706491
- Testing
- pessary handle
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Resilia Inc.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Urinary Incontinence, Overactive Bladder
Tactile Imaging and Electromyography
Urinary incontinence (UI) and overactive bladder (OAB) in women has high prevalence which is increasing with the age. In adults aged 40 and older in the US demonstrated prevalence rate of 27.2% among man and 43.1% among women…
- Trial name
- NCT03477214
- Testing
- Biomechanical and electromyography mapping
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Advanced Tactile Imaging, Inc.
Cystitis
Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)
This study is to assess if the efficacy of cephalosporin is similar to the efficacy of norfloxacin in the acute cystitis treatment.
- Trial name
- CECI (NCT01527019)
- Testing
- Norfloxacin, Cephalosporins
- Sponsor
- Eurofarma Laboratorios S.A.
Urinary Bladder, Neurogenic
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old.
- Trial name
- NCT01557244
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin
- Where
- 84 sites in United States, Belgium and 23 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Bladder Cancers
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
The purpose of the study is the identification of chromosomal aberrations in urine samples. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of UroVysion…
- Trial name
- NCT01264744
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Applied Spectral Imaging Ltd.